# Evaluating LP-10 in Subjects With OLP

> **NCT06233591** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Lipella Pharmaceuticals, Inc.** · enrollment: 24 (estimated)

## Conditions studied

- Oral Lichen Planus

## Interventions

- **DRUG:** LP-10 (Liposomal Tacrolimus)

## Key facts

- **NCT ID:** NCT06233591
- **Lead sponsor:** Lipella Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2025-06-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06233591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06233591, "Evaluating LP-10 in Subjects With OLP". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06233591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*